Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Blinatumomab efficacy differs between newly diagnosed and relapsed/refractory B-ALL: Impact on MRD clearance and survival

View Full Paper
Ask AI
Bookmark
Share

Authors

YSYanping SunFLFei LuJYJingjing Ye

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows blinatumomab improves MRD clearance and survival in newly diagnosed B-ALL, highlighting suboptimal outcomes in relapsed cases.

Key Points

  • Blinatumomab induces high rates of complete remission in newly diagnosed B-ALL, with 100% 12-month PFS among MRD-negative patients.
  • Progression-free survival was significantly higher in newly diagnosed B-ALL patients at 82.5% versus 55.6% in relapsed/refractory cases.
  • Observational analysis of 113 B-ALL patients treated with blinatumomab assessed MRD clearance and survival outcomes using established criteria.
  • May enable better treatment strategies in relapsed B-ALL, emphasizing the importance of targeted therapy for improved outcomes.

Cite This Study

Sun et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d559https://doi.org/10.1182/blood-2025-6307
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Updated results of A phase II study of blinatumomab in adults with measurable residual disease of 10-4 or higher2025
  2. 2Blinatumomab demonstrates MRD eradication in MRD-positive/chemotherapy-delayed pediatric B-ALL and high response in relapsed/refractory cases: a multicenter cohort study2025
  3. 3“upfront use of blinatumomab in adolescents and adults with Philadelphia Chromosome–Negative B-cell acute lymphoblastic leukemia: A systematic review and proportional meta-analysis”2025
  4. 4Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: improved efficacy and reduced toxicity2025
  5. 5T-cell engaging bispecific antibody shows potent MRD negativity with variable remission and survival outcomes: A bayesian meta-analysis of randomized controlled trials2025